Cancer Drugs Will Continue To Command High Prices, Scully Predicts

The transformation in the Medicare market will not prevent cancer drugs from commanding very high prices, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Washington Research Group's annual symposium Nov. 5